Core Insights - Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol Cyclo™ targeting Niemann-Pick Disease Type C1 is fully enrolled, with interim analysis results expected in mid-2025 [1] - Rafael Holdings has successfully merged with Cyclo Therapeutics, positioning itself as a late-stage clinical development company focused on bringing new treatments to market [2][4] - Bill Conkling will transition from CEO to an advisory role, with Howard Jonas taking over as CEO, ensuring continuity in leadership during the critical phase of the clinical trial [3][4] Company Overview - Rafael Holdings, Inc. is involved in clinical and early-stage pharmaceutical ventures, including its subsidiary Cyclo Therapeutics, which is developing Trappsol Cyclo™ for Niemann-Pick Disease Type C1 [5] - The company also holds majority interests in several other pharmaceutical and medical device companies, indicating a diversified portfolio in the healthcare sector [5]